Clinical trials: Endometrioid Endometrial Cancer
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back…
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05538897
- Testing
- Biospecimen Collection, Computed Tomography, Ipatasertib
- Where
- 152 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University
Cervical Carcinoma, Endometrioid Adenocarcinoma
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer.
- Conditions
- Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma
- Trial name
- NCT03345784
- Testing
- Adavosertib, Cisplatin, External Beam Radiation Therapy
- Where
- 8 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic).
- Conditions
- Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01935934
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 19 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Endometrial Neoplasms, Endometrial Neoplasm Malignant
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion.
- Conditions
- Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I, Carcinoma, Endometrioid
- Trial name
- NCT05945407
- Testing
- Indication-extended Fertility-sparing Therapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking University People's Hospital
Non Endometrioid Carcinoma, Endometrioid Carcinoma
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
The aim of this trial is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).
- Trial name
- SENTIRAD (NCT02598219)
- Testing
- Pre-operative SN mapping with radionucleide, Intra-operative SN mapping with patent V blue dye, Intra-operative SN mapping with indocyanin green
- Where
- 16 sites in France
- Volunteers
- 262 people
- Sponsor
- Centre Oscar Lambret
Endometrioid Carcinoma, Clear Cell Carcinoma
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma.
- Conditions
- Endometrioid Carcinoma, Clear Cell Carcinoma, Endometriosis
- Trial name
- EAOC (NCT01732432)
- Sponsor
- University Hospital, Basel, Switzerland
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
- Trial name
- NCT06689956
- Testing
- Non-Interventional Study
- Where
- 20 sites in United States, Austria and 8 more
- Volunteers
- 212 people
- Sponsor
- Mayo Clinic
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin…
- Trial name
- MA-EEC (NCT05332483)
- Testing
- Megestrol Acetate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sunnybrook Health Sciences Centre
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not…
- Conditions
- Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT03924245
- Testing
- Entinostat, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Endometrial Cancer, Metastasis
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic.
- Conditions
- Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma
- Trial name
- NCT05542407
- Testing
- Atezolizumab, ONC201
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05112601
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 138 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Endometrial Cancer, Papillary Serous
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
The purpose of this study is to determine the progression-free survival of patients with surgically staged, Stage I-II papillary serous, clear cell, or endometrioid carcinomas with high-intermediate risk factors treated by…
- Conditions
- Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
- Trial name
- NCT00542490
- Testing
- Vaginal Cuff Brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Oklahoma
Ovarian Cancer, Relapsed Ovarian Cancer
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a…
- Conditions
- Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ACTOv (NCT05080556)
- Testing
- Carboplatin
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)